IFRX

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

📰 Latest News

InflaRx N.V. pioneers C5a inhibition for autoimmune and inflammatory diseases, offering a novel approach with vilobelimab, a first-in-class monoclonal antibody, targeting unmet needs in hidradenitis suppurativa and other severe conditions, positioning them for significant growth in the biotechnology sector.

About IFRX

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on developing inhibitors using C5a technology. Their lead product candidate, vilobelimab, is being developed for various autoimmune and inflammatory diseases.

InflaRx N.V. Company Overview

InflaRx N.V., founded in 2007 and headquartered in Jena, Germany, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative inhibitors targeting the complement component C5a. C5a is a potent inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. The company's core technology revolves around modulating C5a activity to address unmet medical needs in severe and chronic conditions. InflaRx's lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody. Vilobelimab has completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare and debilitating systemic inflammatory skin disease. Additionally, vilobelimab is in Phase II trials for anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis, a life-threatening autoimmune disease, and a Phase IIa exploratory study for pyoderma gangraenosum, a chronic inflammatory skin disorder. Furthermore, it is in Phase II clinical development for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma. Beyond vilobelimab, InflaRx is developing INF904, an oral, small molecule drug candidate for undisclosed chronic inflammatory and autoimmune diseases, and IFX002, in the pre-clinical stage for treating chronic inflammation and autoimmune diseases. InflaRx collaborates with Beijing Defengrei Biotechnology Co. Ltd. and has a clinical trial collaboration and supply agreement with Merck & Co. Inc. Formerly known as Fireman B.V., the company rebranded as InflaRx N.V. in 2017, marking a strategic shift towards its current focus.

Investment Thesis

InflaRx presents a compelling investment opportunity due to its innovative C5a inhibition technology and the potential of vilobelimab to address significant unmet needs in autoimmune and inflammatory diseases. The successful completion of the Phase III trial for hidradenitis suppurativa positions vilobelimab for potential regulatory approval and commercialization, representing a near-term value driver. Further value can be unlocked through the ongoing Phase II trials for ANCA-associated vasculitis, pyoderma gangraenosum, and cutaneous squamous cell carcinoma. The company's early-stage pipeline, including INF904 and IFX002, provides long-term growth potential. With a market cap of approximately $0.06 billion, InflaRx offers significant upside potential if vilobelimab achieves commercial success and the pipeline progresses. The company's collaborations with Beijing Defengrei Biotechnology Co. Ltd. and Merck & Co. Inc. further validate its technology and provide access to resources and expertise.

Key Financial Highlights

• Market capitalization of $0.06 billion reflects the company's current valuation and growth potential.
• Negative P/E ratio of -1.28 indicates the company is currently unprofitable, typical for clinical-stage biopharmaceutical companies.
• Profit margin of -63818.9% highlights the significant R&D investment and lack of product revenue at this stage.
• Gross margin of -8223.1% reflects the high cost of clinical trials and manufacturing preparations prior to product launch.
• Beta of 1.50 suggests the stock is more volatile than the market, typical for biotechnology companies with binary clinical trial outcomes.

Industry Context

InflaRx operates within the competitive biotechnology industry, which is characterized by high R&D costs, regulatory hurdles, and binary outcomes. The market for autoimmune and inflammatory disease treatments is substantial and growing, driven by an aging population and increased prevalence of these conditions. Key market trends include the development of targeted therapies and personalized medicine approaches. InflaRx's C5a inhibition technology positions it within the innovative segment of the market, competing with companies developing alternative approaches to modulate the immune system. Competitors like ARTV, ATYR, CNTB, CNTX, and IMA are also pursuing novel therapies in related areas, but InflaRx's focus on C5a provides a unique angle.

Growth Opportunities

• Hidradenitis Suppurativa (HS) Market: The successful Phase III trial of vilobelimab in HS positions InflaRx to capture a significant share of this market. The HS market is estimated to reach billions of dollars, with limited effective treatment options currently available. Regulatory approval and commercial launch of vilobelimab for HS represent a major growth catalyst for InflaRx. The timeline for potential approval is within the next 1-2 years, pending regulatory review.
• ANCA-Associated Vasculitis Market: The ongoing Phase II trial of vilobelimab in ANCA-associated vasculitis offers another significant growth opportunity. This rare and life-threatening autoimmune disease has a high unmet need for more effective therapies. Positive results from the Phase II trial could lead to further development and potential commercialization, expanding InflaRx's market reach. The timeline for Phase II completion is estimated within the next 12-18 months.
• Pyoderma Gangraenosum Market: The Phase IIa exploratory study of vilobelimab in pyoderma gangraenosum provides an opportunity to address another chronic inflammatory skin disorder. While the market size is smaller than HS, successful development could provide a valuable addition to InflaRx's portfolio. The exploratory nature of the study means timelines are less defined, but initial data could be available within the next year.
• Cutaneous Squamous Cell Carcinoma Market: The Phase II clinical development of vilobelimab for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma represents a potential expansion into the oncology space. This market is significant, and addressing resistance to existing therapies is a major challenge. Positive results could open up new avenues for InflaRx. Clinical data is expected within the next 2 years.
• INF904 Development: The development of INF904, an oral, small molecule drug candidate for undisclosed chronic inflammatory and autoimmune diseases, provides a long-term growth opportunity. Oral therapies offer convenience and potentially broader market access compared to intravenous treatments. While the specific indications are undisclosed, successful development could significantly expand InflaRx's pipeline and market potential. The timeline for clinical development is several years.

Competitive Advantages

• Proprietary C5a inhibition technology platform.
• First-in-class anti-C5a monoclonal antibody (vilobelimab).
• Strong intellectual property protection for its drug candidates.
• Clinical trial data demonstrating efficacy and safety.
• Established collaborations with leading pharmaceutical companies.

Strengths

• Novel C5a inhibition technology.
• First-in-class vilobelimab with Phase III data.
• Pipeline of drug candidates targeting multiple indications.
• Collaborations with established pharmaceutical companies.

Weaknesses

• Clinical-stage company with no currently approved products.
• High R&D costs and reliance on clinical trial success.
• Limited financial resources compared to larger pharmaceutical companies.
• Negative profit and gross margins.

Opportunities

• Regulatory approval and commercialization of vilobelimab.
• Expansion of vilobelimab into additional indications.
• Advancement of INF904 and IFX002 through clinical development.
• Potential for partnerships or acquisitions.

Threats

• Clinical trial failures.
• Regulatory setbacks.
• Competition from other therapies.
• Patent challenges.

What IFRX Does

• Discovers and develops inhibitors using C5a technology.
• Focuses on treating autoimmune and inflammatory diseases.
• Develops vilobelimab, a first-in-class anti-C5a monoclonal antibody.
• Conducts clinical trials for hidradenitis suppurativa, ANCA-associated vasculitis, pyoderma gangraenosum, and cutaneous squamous cell carcinoma.
• Develops INF904, an oral, small molecule drug candidate.
• Develops IFX002 for chronic inflammation and autoimmune diseases.

Business Model

• Develops and patents novel therapeutic candidates.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Potentially commercializes approved products directly or through partnerships.
• Out-licenses or co-develops products with other pharmaceutical companies.

Key Customers

• Patients suffering from autoimmune and inflammatory diseases.
• Hospitals and clinics that treat these patients.
• Pharmaceutical companies seeking to expand their product portfolios through partnerships or acquisitions.
• Healthcare providers prescribing treatments for autoimmune and inflammatory conditions.

Competitors

• Atea Pharmaceuticals Inc (ARTV): Focuses on antiviral therapies.
• aTyr Pharma Inc (ATYR): Develops tRNA synthetase-based therapies.
• Connect Biopharma Holdings Ltd (CNTB): Focuses on autoimmune and inflammatory diseases.
• Context Therapeutics Inc (CNTX): Develops therapies for hormone-driven cancers.
• Imara Inc (IMA): Develops therapies for rare genetic blood disorders.

Catalysts

• Upcoming: Potential regulatory approval and commercial launch of vilobelimab for hidradenitis suppurativa.
• Upcoming: Data readout from the Phase II trial of vilobelimab in ANCA-associated vasculitis.
• Upcoming: Data readout from the Phase IIa exploratory study of vilobelimab in pyoderma gangraenosum.
• Upcoming: Clinical data from the Phase II development of vilobelimab for cutaneous squamous cell carcinoma.
• Ongoing: Continued development of INF904 and IFX002.

Risks

• Potential: Clinical trial failures for vilobelimab or other drug candidates.
• Potential: Regulatory delays or rejection of vilobelimab.
• Potential: Competition from existing or emerging therapies.
• Ongoing: High cash burn rate and need for additional financing.
• Ongoing: Dependence on key personnel and collaborators.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Biotechnology

Browse More

Next Steps